GlaxoSmithKline's Nucala Success, And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha]
GlaxoSmithKline PLC (GSK)
US:NYSE Investor Relations:
gsk.com/en-gb/investors
Company Research
Source: Seeking Alpha
SummaryGlaxoSmithKline's Nucala met its primary endpoint in a pivotal study.Incyte reported positive data from a phase 3 trial of Ruxolitinib.XBiotech shot up on plasma program update.GlaxoSmithKline's Nucala Achieves Co-Primary EndpointsGlaxoSmithKline (GSKannouncedGlaxoSmithKline stated that this is the first time an anti-IL5 biologic has produced positive results in Phase 3 trials pertaining chronic rhinosinusitis. The co-primary endpoints pertained to the size of nasal polyps at week 52 and nasal obstruction during weeks 49 to 52. The drug candidate showed statistically significant improvement on both the accounts. It also showed statistically significant progress for the time to first actual nasal surgery up to week 52, which constituted key secondary endpoint for the trial.SYNAPSE is the first trial aimed at assessing the use of biologic for treating patients with previous history of surgeries and requiring further surgery due to severe symptoms and increase in the size of their
Show less
Read more
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GSK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GSK alerts
High impacting GlaxoSmithKline PLC news events
Weekly update
A roundup of the hottest topics
GSK
News
- GSK (NYSE:GSK) had its "hold" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.MarketBeat
- GSK (NYSE:GSK) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- Jefferies Reaffirms a Buy Rating on GSK plc (GSK) – Here's Why [Yahoo! Finance]Yahoo! Finance
- GSK (NYSE:GSK) was downgraded by analysts at Barclays PLC from an "equal weight" rating to an "underweight" rating.MarketBeat
- Why is GSK plc (GSK) One of the Best Affordable Healthcare Stocks to Buy Now? [Yahoo! Finance]Yahoo! Finance
GSK
Sec Filings
- 1/16/26 - Form 6-K
- 1/15/26 - Form 6-K
- 1/13/26 - Form 6-K
- GSK's page on the SEC website